Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOKI: Optimizing Lymphodepletion for CAR T Cell Therapy in DLBCL
NCT06003179Phase 1Withdrawn
- Sponsor
- University Health Network
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cyclophosphamide in diffuse large B-cell lymphoma (DLBCL) (6 arms), sponsored by University Health Network. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicity. Planned start Apr 2024; status: withdrawn.
02
Drugs
cyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06003179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003179.